Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.12 (
PKG
)
2,515
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Two-pore domain potassium (K(2P)) channels are proposed to underlie the background or leak current found in many excitable cells. Extensive studies have been performed investigating the inhibition of K(2P)2.1 by Galpha(q)- and Galpha(s)-coupled G-protein-coupled receptors (GPCRs), whereas in the present study we investigate the mechanisms underlying Galpha(i)/Galpha(o)-coupled GPCR increases in K(2P)2.1 activity. Activation of
mGlu4
increases K(2P)2.1 activity, with pharmacological inhibition of protein kinases and phosphatases revealing the involvement of PKA whereas PKC,
PKG
or protein phosphatases play no role. Mutational analysis of potential C-terminal phosphorylation sites indicates S333 to control approximately 70%, with S300 controlling approximately 30% of the increase in K(2P)2.1 activity following
mGlu4
activation. These data reveal that activation of
mGlu4
leads to an increase in K(2P)2.1 activity through a reduction in C-terminal phosphorylation, which represents a novel mechanism by which group III mGlu receptors may regulate cell excitability and synaptic activity.
...
PMID:mGlu4 potentiation of K(2P)2.1 is dependant on C-terminal dephosphorylation. 1791 32